Company / Operating Cash Flow
Bionano Genomics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$16.3M
FY2025
5-year range
-$125.2M / -$16.3M
FY2021-FY2025
Trend
+76.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$125M to -$16M over the past 2 years.
Based on SEC 10-K filings.
-$16M in FY2025.
Improved from -$125M to -$16M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 76.3% year-over-year.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$16.3M | +76.3% |
| FY2024 | -$68.9M | +44.9% |
| FY2023 | -$125.2M | -0.3% |
| FY2022 | -$124.8M | -73.5% |
| FY2021 | -$71.9M | -87.7% |
| FY2020 | -$38.3M | -29.7% |
| FY2019 | -$29.5M | -48.1% |
| FY2018 | -$19.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026